Shark mouth pancreaticojejunostomy: a new enteric reconstruction procedure of pancreatic stump.


Journal

Chinese medical journal
ISSN: 2542-5641
Titre abrégé: Chin Med J (Engl)
Pays: China
ID NLM: 7513795

Informations de publication

Date de publication:
05 Jun 2019
Historique:
pubmed: 22 3 2019
medline: 18 12 2019
entrez: 22 3 2019
Statut: ppublish

Résumé

The enteric reconstruction procedure of pancreatic stump after pancreaticoduodenectomy remains to be the critical factor influencing the mortality and morbidity. No widely accepted surgical procedure for the pancreaticojejunostomy has been erected yet. We have developed a new technique of pancreaticojejunostomy named "shark mouth pancreaticojejunostomy." The aim of this study is to assess the efficacy of "shark mouth pancreaticojejunostomy." This is a prospective single-arm observational study to evaluate the clinical efficacy of "shark mouth pancreaticojejunostomy." Patients with diseases, in whom a pancreaticoduodenectomy is indicated, would be recruited from Peking University Third Hospital. The hypothesis to be tested is that a "shark mouth pancreaticojejunostomy" will reduce fistula rate from around 20% to less than 10%. A sample size of 120 patients will be needed. The primary endpoint is the incidence rate of postoperative pancreatic fistula (POPF). The secondary endpoints of the study are anastomosis time, postoperative hospital stay, and morbidities besides the POPF such as the hemorrhage. Enrolled patients will undergo pancreaticoduodenectomy and be followed up for 3 months. The relevant data will be monitored and recorded. The current trial will explore the therapeutic value of the newly raised pancreaticojejunostomy procedure as the "shark mouth pancreaticojejunostomy." Its theoretical base and pragmatic feature will promise high external validity. Clinical Trials.gov: NCT03366038; https://www.clinicaltrials.gov.

Sections du résumé

BACKGROUND BACKGROUND
The enteric reconstruction procedure of pancreatic stump after pancreaticoduodenectomy remains to be the critical factor influencing the mortality and morbidity. No widely accepted surgical procedure for the pancreaticojejunostomy has been erected yet. We have developed a new technique of pancreaticojejunostomy named "shark mouth pancreaticojejunostomy." The aim of this study is to assess the efficacy of "shark mouth pancreaticojejunostomy."
METHODS METHODS
This is a prospective single-arm observational study to evaluate the clinical efficacy of "shark mouth pancreaticojejunostomy." Patients with diseases, in whom a pancreaticoduodenectomy is indicated, would be recruited from Peking University Third Hospital. The hypothesis to be tested is that a "shark mouth pancreaticojejunostomy" will reduce fistula rate from around 20% to less than 10%. A sample size of 120 patients will be needed. The primary endpoint is the incidence rate of postoperative pancreatic fistula (POPF). The secondary endpoints of the study are anastomosis time, postoperative hospital stay, and morbidities besides the POPF such as the hemorrhage. Enrolled patients will undergo pancreaticoduodenectomy and be followed up for 3 months. The relevant data will be monitored and recorded.
CONCLUSIONS CONCLUSIONS
The current trial will explore the therapeutic value of the newly raised pancreaticojejunostomy procedure as the "shark mouth pancreaticojejunostomy." Its theoretical base and pragmatic feature will promise high external validity.
TRIAL REGISTRATION BACKGROUND
Clinical Trials.gov: NCT03366038; https://www.clinicaltrials.gov.

Identifiants

pubmed: 30896569
doi: 10.1097/CM9.0000000000000219
pmc: PMC6629351
doi:

Banques de données

ClinicalTrials.gov
['NCT03366038']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1354-1358

Références

Eur J Surg Oncol. 1999 Apr;25(2):113-23
pubmed: 10218451
Ann Surg. 2000 Dec;232(6):786-95
pubmed: 11088073
Surgery. 2005 Jul;138(1):8-13
pubmed: 16003309
J Hepatobiliary Pancreat Surg. 2006;13(3):185-9
pubmed: 16708292
Ann Surg. 2007 Mar;245(3):443-51
pubmed: 17435552
Ann Surg. 2007 Aug;246(2):269-80
pubmed: 17667506
J Hepatobiliary Pancreat Surg. 2008;15(3):247-51
pubmed: 18535760
J Am Coll Surg. 2009 May;208(5):738-47; discussion 747-9
pubmed: 19476827
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
Surg Today. 2010 Nov;40(11):1011-7
pubmed: 21046497
Surg Today. 2011 Jun;41(6):761-6
pubmed: 21626319
Lancet Oncol. 2013 Jun;14(7):573-5
pubmed: 23643140
J Gastrointest Surg. 2014 Mar;18(3):464-75
pubmed: 24448997
Surgery. 2014 Jan;155(1):47-57
pubmed: 24694359
Surgery. 2017 May;161(5):1221-1234
pubmed: 28027816
Surgery. 2017 Mar;161(3):584-591
pubmed: 28040257
Hepatobiliary Pancreat Dis Int. 2017 Oct 15;16(5):537-544
pubmed: 28992887

Auteurs

Hang-Yan Wang (HY)

Department of General Surgery, Peking University Third Hospital, Beijing 100191, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH